ANEB
Anebulo Pharmaceuticals Inc

179
Mkt Cap
$40.38M
Volume
4,391.00
52W High
$3.42
52W Low
$0.2999
PE Ratio
-5.05
ANEB Fundamentals
Price
$0.9799
Prev Close
$0.99
Open
$0.98
50D MA
$0.7103
Beta
0.16
Avg. Volume
51,526.73
EPS (Annual)
-$0.2509
P/B
5.07
Rev/Employee
$0.00
$37.07
Loading...
Loading...
News
all
press releases
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·2mo ago
News Placeholder
More News
News Placeholder
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·2mo ago
News Placeholder
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·2mo ago
News Placeholder
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·2mo ago
News Placeholder
How Is The Market Feeling About Anebulo Pharmaceuticals Inc?
read more...
Benzinga·3mo ago
News Placeholder
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·3mo ago
News Placeholder
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading 0.8% Higher - Still a Buy?
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Up 0.8% - Here's Why...
MarketBeat·4mo ago
News Placeholder
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·5mo ago
<
...
1
>

Latest ANEB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.